Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Canadian Cancer Trials Group
Janssen Pharmaceutical K.K.
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
University of California, Davis
Dana-Farber Cancer Institute
Emory University
Emory University
Eli Lilly and Company
University of Colorado, Denver
National Cancer Institute (NCI)
University of Kentucky
Exelixis
Dana-Farber Cancer Institute
Exelixis
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Washington University School of Medicine
Eli Lilly and Company
Washington University School of Medicine
Eastern Cooperative Oncology Group
Dana-Farber Cancer Institute
Baylor College of Medicine
University of Cincinnati